Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.26
Equity-to-Asset	0.3
Debt-to-Equity	1.19
Debt-to-EBITDA	1.95
Interest Coverage	12.11
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.25	Distress Grey Safe
Beneish M-Score	-2.77	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	3.7
	3-Year EBITDA Growth Rate	-4.7
	3-Year EPS without NRI Growth Rate	-1
	3-Year FCF Growth Rate	1.2
	3-Year Book Growth Rate	-4.8
	Future 3-5Y EPS without NRI Growth Rate Estimate	5.67
	Future 3-5Y Total Revenue Growth Rate Estimate	3.73

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	48.27
	9-Day RSI	41.09
	14-Day RSI	42.28
	6-1 Month Momentum %	22.52
	12-1 Month Momentum %	9.05

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.26
	Quick Ratio	0.97
	Cash Ratio	0.33
	Days Inventory	180.6
	Days Sales Outstanding	70.09
	Days Payable	86.4

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.58
	Dividend Payout Ratio	0.51
	3-Year Dividend Growth Rate	1.8
	Forward Dividend Yield %	3.58
	5-Year Yield-on-Cost %	4.07
	3-Year Average Share Buyback Ratio	2.2
	Shareholder Yield %	1

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	73.1
	Operating Margin %	24.27
	Net Margin %	17.53
	FCF Margin %	18.73
	ROE %	37.58
	ROA %	11.77
	ROIC %	16.85
	3-Year ROIIC %	-44.01
	ROC (Joel Greenblatt) %	54.73
	ROCE %	22.29
	Years of Profitability over Past 10-Year	10

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	20.27
	Forward PE Ratio	13.11
	PE Ratio without NRI	14.35
	Shiller PE Ratio	19.34
	Price-to-Owner-Earnings	18.88
	PEG Ratio	11.96
	PS Ratio	3.56
	PB Ratio	7.39
	Price-to-Tangible-Book	130.29
	Price-to-Free-Cash-Flow	19
	Price-to-Operating-Cash-Flow	13.38
	EV-to-EBIT	16.84
	EV-to-Forward-EBIT	11.1
	EV-to-EBITDA	13.63
	EV-to-Forward-EBITDA	9.76
	EV-to-Revenue	3.99
	EV-to-Forward-Revenue	3.77
	EV-to-FCF	21.28
	Price-to-Projected-FCF	1.34
	Price-to-DCF (Earnings Based)	0.89
	Price-to-DCF (FCF Based)	1.18
	Price-to-Median-PS-Value	0.81
	Price-to-Graham-Number	9.13
	Earnings Yield (Greenblatt) %	5.94
	FCF Yield %	5.26
	Forward Rate of Return (Yacktman) %	7.44

GF Value: CHF333.21

XSWX:ROG

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with ROG. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.